Transcription factor KLF2 enhances the sensitivity of breast cancer cells to cisplatin by suppressing kinase WEE1

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492. PMID: 30207593.
   PubMed Web of Science ®Google Scholar
• Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–289. doi:10.1016/S1470-2045(13)70567-9. PMID: 24872111.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–1150. doi:10.1016/S0140-6736(16)31891-8. PMID: 27865536.
   PubMed Web of Science ®Google Scholar
• Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010;16(1):53–61. doi:10.1097/PPO.0b013e3181d24ff7. PMID: 20164691.
   PubMed Web of Science ®Google Scholar
• Turner NC, Neven P, Loibl S, Andre F. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. Lancet. 2017;389(10087):2403–2414. doi:10.1016/S0140-6736(16)32419-9. PMID: 27939057.
   PubMed Web of Science ®Google Scholar
• Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415–2429. doi:10.1016/S0140-6736(16)32417-5. PMID: 27939064.
   PubMed Web of Science ®Google Scholar
• Cancer Genome AN. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature11412. PMID: 23000897.
   PubMed Web of Science ®Google Scholar
• Fasching PA, Brucker SY, Fehm TN, Overkamp F, Janni W, Wallwiener M, Hadji P, Belleville E, Haberle L, Taran FA, et al. Biomarkers in patients with metastatic breast cancer and the PRAEGNANT study network. Geburtshilfe Frauenheilkd. 2015;75(1):41–50. 10.1055/s-0034-1396215. PMID: 25684786.
   PubMed Web of Science ®Google Scholar
• Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini KS, Sotiriou C, et al. The AURORA initiative for metastatic breast cancer. Br J Cancer. 2014;111(10):1881–1887. 10.1038/bjc.2014.341. PMID: 25225904.
   PubMed Web of Science ®Google Scholar
• Dickson MA, Carvajal RD, Merrill AH Jr., Gonen M, Cane LM, Schwartz GK. A phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin Cancer Res. 2011;17(8):2484–2492. doi:10.1158/1078-0432.CCR-10-2323. PMID: 21257722.
   PubMed Web of Science ®Google Scholar
• Hu XC, Zhang J, Xu BH, Cai L, Ragaz J, Wang ZH, Wang BY, Teng YE, Tong ZS, Pan YY, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2015;16(4):436–446. 10.1016/S1470-2045(15)70064-1. PMID: 25795409.
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, et al. TBCRC009: a multicenter Phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol. 2015;33(17):1902–1909. 10.1200/JCO.2014.57.6660. PMID: 25847936.
   PubMed Web of Science ®Google Scholar
• Sun CY, Zhang QY, Zheng GJ, Feng B. Phytochemicals: current strategy to sensitize cancer cells to cisplatin. Biomed Pharmacother. 2019;110:518–527. PMID: 30530287. doi:10.1016/j.biopha.2018.12.010.
   PubMed Web of Science ®Google Scholar
• Keenan TE, Li T, Vallius T, Guerriero JL, Tayob N, Kochupurakkal B, Davis J, Pastorello R, Tahara RK, Anderson L, et al. Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer. Clin Cancer Res. 2021;27(4):983–991. 10.1158/1078-0432.CCR-20-3089. PMID: 33257427.
   PubMed Web of Science ®Google Scholar
• Song Y, Li X, Wang D, Fu C, Zhu Z, Zou MH, Zhu Y. Transcription factor Kruppel-like factor 2 plays a vital role in endothelial colony forming cells differentiation. Cardiovasc Res. 2013;99(3):514–524. doi:10.1093/cvr/cvt113. PMID: 23667185.
   PubMed Web of Science ®Google Scholar
• Boon RA, Leyen TA, Fontijn RD, Fledderus JO, Baggen JM, Volger OL, van Nieuw Amerongen GP, Horrevoets AJ. KLF2-induced actin shear fibers control both alignment to flow and JNK signaling in vascular endothelium. Blood. 2010;115(12):2533–2542. doi:10.1182/blood-2009-06-228726. PMID: 20032497.
   PubMed Web of Science ®Google Scholar
• Basu P, Lung TK, Lemsaddek W, Sargent TG, Williams DC Jr., Basu M, Redmond LC, Lingrel JB, Haar JL, Lloyd JA. EKLF and KLF2 have compensatory roles in embryonic beta-globin gene expression and primitive erythropoiesis. Blood. 2007;110(9):3417–3425. doi:10.1182/blood-2006-11-057307. PMID: 17675555.
   PubMed Web of Science ®Google Scholar
• Wang F, Zhu Y, Huang Y, McAvoy S, Johnson WB, Cheung TH, Chung TK, Lo KW, Yim SF, Yu MM, et al. Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis. Oncogene. 2005;24(24):3875–3885. 10.1038/sj.onc.1208546. PMID: 15735666.
   PubMed Web of Science ®Google Scholar
• Xie P, Tang Y, Shen S, Wang Y, Xing G, Yin Y, He F, Zhang L. Smurf1 ubiquitin ligase targets Kruppel-like factor KLF2 for ubiquitination and degradation in human lung cancer H1299 cells. Biochem Biophys Res Commun. 2011;407(1):254–259. doi:10.1016/j.bbrc.2011.03.016. PMID: 21382345.
   PubMed Web of Science ®Google Scholar
• Li Y, Tu S, Zeng Y, Zhang C, Deng T, Luo W, Lian L, Chen L, Xiong X, Yan X. KLF2 inhibits TGF-beta-mediated cancer cell motility in hepatocellular carcinoma. Acta Biochim Biophys Sin (Shanghai). 2020;52(5):485–494. doi:10.1093/abbs/gmaa024. PMID: 32318691.
   PubMed Web of Science ®Google Scholar
• Lin J, Tan H, Nie Y, Wu D, Zheng W, Lin W, Zhu Z, Yang B, Chen X, Chen T. Kruppel-like factor 2 inhibits hepatocarcinogenesis through negative regulation of the Hedgehog pathway. Cancer Sci. 2019;110(4):1220–1231. doi:10.1111/cas.13961. PMID: 30719823.
   PubMed Web of Science ®Google Scholar
• Hu CC, Liang YW, Hu JL, Liu LF, Liang JW, Wang R. LncRNA RUSC1-AS1 promotes the proliferation of breast cancer cells by epigenetic silence of KLF2 and CDKN1A. Eur Rev Med Pharmacol Sci. 2019;23(15):6602–6611. doi:10.26355/eurrev_201908_18548. PMID: 31378902.
   PubMed Web of Science ®Google Scholar
• Xiao S, Jin-Xiang Y, Long T, Xiu-Rong L, Hong G, Jie-Cheng Y, Fei Z. Kruppel-like factor 2 disturb non-small cell lung cancer energy metabolism by inhibited glutamine consumption. J Pharm Pharmacol. 2020;72(6):843–851. doi:10.1111/jphp.13252. PMID: 32196690.
   PubMed Web of Science ®Google Scholar
• Lorentzen A, Mitchelmore C. NDRG2 gene copy number is not altered in colorectal carcinoma. World J Clin Oncol. 2017;8(1):67–74. doi:10.5306/wjco.v8.i1.67. PMID: 28246586.
   PubMed Web of Science ®Google Scholar
• Lee JO, Kang MJ, Byun WS, Kim SA, Seo IH, Han JA, Moon JW, Kim JH, Kim SJ, Lee EJ, et al. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51. Breast Cancer Res. 2019;21(1):115. 10.1186/s13058-019-1204-2. PMID: 31640742.
   PubMed Web of Science ®Google Scholar
• Zdraveski ZZ, Mello JA, Marinus MG, Essigmann JM. Multiple pathways of recombination define cellular responses to cisplatin. Chem Biol. 2000;7(1):39–50. doi:10.1016/s1074-5521(00)00064-8. PMID: 10662689.
   PubMedGoogle Scholar
• Crul M, Schellens JH, Beijnen JH, Maliepaard M. Cisplatin resistance and DNA repair. Cancer Treat Rev. 1997;23(5–6):341–366. doi:10.1016/s0305-7372(97)90032-3. PMID: 9465884.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257. PMID: 24874729. doi:10.1038/cddis.2013.428.
   PubMed Web of Science ®Google Scholar
• Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27–36. PMID: 26804248. doi:10.1016/j.phrs.2016.01.001.
   PubMed Web of Science ®Google Scholar
• Wu J, Lingrel JB. KLF2 inhibits Jurkat T leukemia cell growth via upregulation of cyclin-dependent kinase inhibitor p21WAF1/CIP1. Oncogene. 2004;23(49):8088–8096. doi:10.1038/sj.onc.1207996. PMID: 15361832.
   PubMed Web of Science ®Google Scholar
• Coleman TR, Dunphy WG. Cdc2 regulatory factors. Curr Opin Cell Biol. 1994;6(6):877–882. doi:10.1016/0955-0674(94)90060-4. PMID: 7880537.
   PubMed Web of Science ®Google Scholar
• Kellogg DR. Wee1-dependent mechanisms required for coordination of cell growth and cell division. J Cell Sci. 2003;116(24):4883–4890. doi:10.1242/jcs.00908. PMID: 14625382.
   PubMed Web of Science ®Google Scholar
• Walworth NC. DNA damage: chk1 and Cdc25, more than meets the eye. Curr Opin Genet Dev. 2001;11(1):78–82. doi:10.1016/s0959-437x(00)00160-x. PMID: 11163155.
   PubMed Web of Science ®Google Scholar
• Iorns E, Lord CJ, Grigoriadis A, McDonald S, Fenwick K, Mackay A, Mein CA, Natrajan R, Savage K, Tamber N, et al. Integrated functional, gene expression and genomic analysis for the identification of cancer targets. PLoS One. 2009;4(4):e5120. 10.1371/journal.pone.0005120. PMID: 19357772.
   PubMed Web of Science ®Google Scholar
• Murrow LM, Garimella SV, Jones TL, Caplen NJ, Lipkowitz S. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat. 2010;122(2):347–357. doi:10.1007/s10549-009-0571-2. PMID: 19821025.
   PubMed Web of Science ®Google Scholar
• Stathis A, Oza A. Targeting Wee1-like protein kinase to treat cancer. Drug News Perspect. 2010;23(7):425–429. doi:10.1358/dnp.2010.23.7.1490760. PMID: 20862394.
   PubMedGoogle Scholar
• Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak AR, Lam R, Demuth T, Rose S, Lee MA, et al. Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J Clin Oncol. 2016;34(36):4371–4380. 10.1200/JCO.2016.67.5991. PMID: 27601554.
   PubMed Web of Science ®Google Scholar
• Mendez E, Rodriguez CP, Kao MC, Raju S, Diab A, Harbison RA, Konnick EQ, Mugundu GM, Santana-Davila R, Martins R, et al. A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2018;24(12):2740–2748. 10.1158/1078-0432.CCR-17-3796. PMID: 29535125.
   PubMed Web of Science ®Google Scholar
• Cole KA, Pal S, Kudgus RA, Ijaz H, Liu X, Minard CG, Pawel BR, Maris JM, Haas-Kogan DA, Voss SD, et al. Phase I clinical trial of the Wee1 inhibitor adavosertib (AZD1775) with irinotecan in children with relapsed solid tumors: a COG Phase I consortium report (ADVL1312). Clin Cancer Res. 2020;26(6):1213–1219. 10.1158/1078-0432.CCR-19-3470. PMID: 31857431.
   PubMed Web of Science ®Google Scholar
• Chen D, Lin X, Gao J, Shen L, Li Z, Dong B, Zhang C, Zhang X. Wee1 Inhibitor AZD1775 Combined with Cisplatin Potentiates Anticancer Activity against Gastric Cancer by Increasing DNA Damage and Cell Apoptosis. Biomed Res Int. 2018;2018:5813292. PMID: 29977914. doi:10.1155/2018/5813292.
   PubMed Web of Science ®Google Scholar
• Matheson CJ, Venkataraman S, Amani V, Harris PS, Backos DS, Donson AM, Wempe MF, Foreman NK, Vibhakar R, Reigan P. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells. ACS Chem Biol. 2016;11(4):921–930. doi:10.1021/acschembio.5b00725. PMID: 26745241.
   PubMed Web of Science ®Google Scholar
• Zheng H, Shao F, Martin S, Xu X, Deng CX. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance. Sci Rep. 2017;7(1):43517. doi:10.1038/srep43517. PMID: 28262781.
   PubMedGoogle Scholar
• Wang HG, Cao B, Zhang LX, Song N, Li H, Zhao WZ, Li YS, Ma SM, Yin DJ. KLF2 inhibits cell growth via regulating HIF-1alpha/Notch-1 signal pathway in human colorectal cancer HCT116 cells. Oncol Rep. 2017;38(1):584–590. doi:10.3892/or.2017.5708. PMID: 28628187.
   PubMed Web of Science ®Google Scholar
• Zhuang T, Liu J, Chen X, Zhang L, Pi J, Sun H, Li L, Bauer R, Wang H, Yu Z, et al. Endothelial foxp1 suppresses atherosclerosis via modulation of Nlrp3 inflammasome activation. Circ Res. 2019;125(6):590–605. 10.1161/CIRCRESAHA.118.314402. PMID: 31318658.
   PubMed Web of Science ®Google Scholar
• Xu M, Chen X, Lin K, Zeng K, Liu X, Pan B, Xu X, Xu T, Hu X, Sun L, et al. The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p. Mol Cancer. 2018;17(1):141. 10.1186/s12943-018-0894-x. PMID: 30266084.
   PubMed Web of Science ®Google Scholar
• Li X, Li Z, Liu Z, Xiao J, Yu S, Song Y. Long non-coding RNA DLEU1 predicts poor prognosis of gastric cancer and contributes to cell proliferation by epigenetically suppressing KLF2. Cancer Gene Ther. 2018;25(3–4):58–67. doi:10.1038/s41417-017-0007-9. PMID: 29282356.
   PubMed Web of Science ®Google Scholar
• Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27(4):710–728. doi:10.1016/j.ymthe.2019.02.012. PMID: 30846391.
   PubMed Web of Science ®Google Scholar
• Sikder S, Gote V, Alshamrani M, Sicotte J, Pal D. Long-term delivery of protein and peptide therapeutics for cancer therapies. Expert Opin Drug Deliv. 2019;16(10):1113–1131. doi:10.1080/17425247.2019.1662785. PMID: 31498012.
   PubMed Web of Science ®Google Scholar
• Pulecio J, Verma N, Mejia-Ramirez E, Huangfu D, Raya A. CRISPR/Cas9-Based Engineering of the Epigenome. Cell Stem Cell. 2017;21(4):431–447. doi:10.1016/j.stem.2017.09.006. PMID: 28985525.
   PubMed Web of Science ®Google Scholar
• Tadic V, Josipovic G, Zoldos V, Vojta A. CRISPR/Cas9-based epigenome editing: an overview of dCas9-based tools with special emphasis on off-target activity. Methods. 2019;164-165:109–119. PMID: 31071448. doi:10.1016/j.ymeth.2019.05.003.
   PubMed Web of Science ®Google Scholar
• Koshy N, Quispe D, Shi R, Mansour R, Burton GV. Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast. 2010;19(3):246–248. doi:10.1016/j.breast.2010.02.003. PMID: 20227277.
   PubMed Web of Science ®Google Scholar
• Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, Pluim D, van Werkhoven E, Rose S, Lee MA, et al. Phase II study of WEE1 Inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 2016;34(36):4354–4361. 10.1200/JCO.2016.67.5942. PMID: 27998224.
   PubMed Web of Science ®Google Scholar